The progressive forms of multiple sclerosis – primary progressive MS (PPMS) and secondary progressive MS (SPMS) – have presented neurologists with particular challenges for decades. Unlike relapsing-remitting MS (RRMS), where inflammation control through disease-modifying therapies is now the clinical standard, therapeutic progress in the progressive spectrum remains fragmentary. In recent years, however, new approaches have emerged: from targeted immunomodulators, Bruton’s tyrosine kinase inhibitors and remyelination strategies to innovative cell and gene therapies.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future
Biomarkers in schizophrenia
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications
Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Parkinson's disease
Individual therapy management for an optimized outcome – an update
- Latent autoimmune diabetes in adults (LADA)